Aktuellt
SENASTE
FluoGuide announced enrolment completion for its ph2b randomised trial of FG001 vs. 5-ALA in aggressive glioma, and expects to report topline in 2-3 months (i.e., probably during November 2023). The trial has a high probability of demonstrating superior removal cancer tissue, in our view, and is yet another impressive example of management's ability to rapidly set up trials and recruit patients.
LÄS MER
